China Approves Fifth Domestic PD-1 Drug
Just Misses Out On Annual Price Negotiations
The latest approval for AnNiKe (penpulimab) from Akeso/Sino Biopharm adds further competition to a crowded space where six PD-1 immuno-oncology drugs elbow each other.
